Supplemental material
OncoImmunology
Volume 7, 2018 - Issue 12
Open access
3,865
Views
28
CrossRef citations to date
0
Altmetric
Original Research
Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses
Jasmin QuandtDepartment of Translational Immunology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany;Knapp Research Center, Section of Rheumatology, Department of Medicine, University of Chicago, Chicago, IL, USA
, Christoph SchludeDepartment of Translational Immunology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany
, Michael BartoschekDepartment of Translational Immunology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany;Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden
http://orcid.org/0000-0002-1567-795X
Rainer WillGenomics and Proteomics Core Facility, German Cancer Research Center (DKFZ), Heidelberg, Germany
, Angel Cid-ArreguiDepartment of Translational Immunology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany;Targeted Tumor Vaccines Group, Clinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany
, Sebastian SchölchDepartment of Visceral Surgery, University Hospital Heidelberg, Heidelberg, Germany;Department of Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
http://orcid.org/0000-0003-0012-3177
Christoph ReissfelderDepartment of Visceral Surgery, University Hospital Heidelberg, Heidelberg, Germany;Department of Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
, Jürgen WeitzDepartment of Visceral, Thoracic, and Vascular Surgery, Medizinische Fakultaet an der TU-Dresden, Dresden, Germany
, Martin SchneiderDepartment of Visceral Surgery, University Hospital Heidelberg, Heidelberg, Germany
, Stefan WiemannGenomics and Proteomics Core Facility, German Cancer Research Center (DKFZ), Heidelberg, Germany;Division Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany
http://orcid.org/0000-0003-4683-3174
Frank MomburgDepartment of Translational Immunology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany;Antigen Presentation and T/NK Cell Activation Group, Clinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany
& Philipp BeckhoveDepartment of Translational Immunology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany;Regensburg Center for Interventional Immunology (RCI), University Regensburg and Department of Hematology-Oncology, Internal Medicine III, University Hospital Regensburg, Regensburg, GermanyCorrespondence[email protected]
show all
Article: e1500671
|
Received 06 Mar 2018, Accepted 10 Jul 2018, Published online: 21 Sep 2018
Related Research Data
Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.
Source:
Rockefeller University Press
Cancer vaccines: should we be targeting patients with less aggressive disease?
Source:
Informa UK Limited
HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patients.
Source:
Informa UK Limited
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
Source:
American Association for the Advancement of Science (AAAS)
Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations.
Source:
MDPI AG
The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors
Source:
Springer Nature
A new era in anticancer peptide vaccines
Source:
Wiley
Melanoma-reactive T cells in the bone marrow of melanoma patients: association with disease stage and disease duration.
Source:
American Association for Cancer Research (AACR)
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
Source:
Springer Science and Business Media LLC
Mechanisms of peptide vaccination in mouse models: tolerance, immunity, and hyperreactivity.
Source:
Elsevier
CD8+ CTL Priming by Exact Peptide Epitopes in Incomplete Freund’s Adjuvant Induces a Vanishing CTL Response, whereas Long Peptides Induce Sustained CTL Reactivity
Source:
The American Association of Immunologists
MUC1 immunobiology: from discovery to clinical applications.
Source:
Elsevier
Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories.
Source:
Humana Press
Pancreatic cancer biology and genetics
Source:
Springer Science and Business Media LLC
Changes in Paracrine Interleukin-2 Requirement, CCR7 Expression, Frequency, and Cytokine Secretion of Human Immunodeficiency Virus-Specific CD4+ T Cells Are a Consequence of Antigen Load
Source:
American Society for Microbiology
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia
Source:
Massachusetts Medical Society
Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis
Source:
American Society for Clinical Investigation
Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras.
Source:
Wiley
Self-Tolerance Does Not Restrict the CD4+ T-Helper Response against the p53 Tumor Antigen
Source:
American Association for Cancer Research (AACR)
Biological properties of human c-Ha-ras1 genes mutated at codon 12
Source:
Springer Science and Business Media LLC
A vaccine targeting mutant IDH1 induces antitumour immunity
Source:
Springer Science and Business Media LLC
Cross-priming in health and disease.
Source:
Springer Science and Business Media LLC
Immunization with mutant p53- and K-ras-derived peptides in cancer patients: Immune response and clinical outcome
Source:
American Society of Clinical Oncology (ASCO)
A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice.
Source:
Wiley
Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines
Source:
Springer Science and Business Media LLC
Cancer Genome Landscapes
Source:
American Association for the Advancement of Science (AAAS)
Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma.
Source:
Proceedings of the National Academy of Sciences
HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T-cells
Source:
American Society of Hematology
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Source:
Springer Science and Business Media LLC
NY-ESO-1: review of an immunogenic tumor antigen.
Source:
Elsevier
Antigen-induced regulatory T cells in autoimmunity
Source:
Springer Science and Business Media LLC
The Frequency of High Avidity T Cells Determines the Hierarchy of Determinant Spreading
Source:
The American Association of Immunologists
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer.
Source:
Springer Science and Business Media LLC
IDENTIFICATION OF OVERLAPPING EPITOPES IN MUTANT RAS ONCOGENE PEPTIDES THAT ACTIVATE CD4+ AND CD8+ T CELL RESPONSES
Source:
Wiley
HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes.
Source:
Springer Science and Business Media LLC
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.